World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
28046
World Ranking
17419
National Ranking
8720

Overview

Branimir I. Sikic is affiliated with Stanford University in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research primarily focuses on oncology, with significant work in molecular biology, cell biology, pediatrics, perinatology, and genetics.

The main topics covered in their work include drug transport and resistance mechanisms, cancer immunotherapy and biomarkers, CAR-T cell therapy research, microtubule and mitosis dynamics, pharmacological effects and toxicity studies, hemoglobinopathies and related disorders, and acute myeloid leukemia research.

Among their recent papers are the following:

  • Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies, 2020, Blood Advances
  • Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors, 2022, Journal for ImmunoTherapy of Cancer
  • Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer, 2023, Cellular and Molecular Life Sciences
  • Drug Resistance and Its Clinical Circumvention, 2022, Holland-Frei Cancer Medicine
  • A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors, 2023, American Journal of Clinical Oncology

Their frequent co-authors include:

  • George E. Durán
  • Thomas Hawthorne
  • Tracey Rawls
  • Tibor Keler
  • Michael Yellin

Branimir I. Sikic's work has been published in several journals and publication venues, including:

  • Cancer Chemotherapy and Pharmacology
  • Blood Advances
  • Journal for ImmunoTherapy of Cancer
  • Cellular and Molecular Life Sciences
  • American Journal of Clinical Oncology

Best Publications

  • Integrated genomic analyses of ovarian carcinoma

    D. Bell;A. Berchuck;M. Birrer;J. Chien

  • Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death

    Charles Dumontet;Branimir I. Sikic

  • First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

    Branimir I. Sikic;Nehal Lakhani;Amita Patnaik;Sumit A. Shah

  • Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity

    Jean-Pierre Marie;Robert Zittoun;Branimir I. Sikic

  • Methods to Detect P-Glycoprotein-associated Multidrug Resistance in Patients' Tumors: Consensus Recommendations

    William T. Beck;Thomas M. Grogan;Cheryl L. Willman;Carlos Cordon-Cardo

  • Gene Expression Patterns in Ovarian Carcinomas

    Marci E. Schaner;Douglas T. Ross;Giuseppe Ciaravino;Therese Sørlie

  • Detection of cell-affecting agents with a silicon biosensor

    JW Parce;JC Owicki;KM Kercso;GB Sigal

  • Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

    B. I. Sikic;George A. Fisher;Bert L. Lum;Joanne Halsey

  • Functional Network Analysis Reveals Extended Gliomagenesis Pathway Maps and Three Novel MYC-Interacting Genes in Human Gliomas

    Markus Bredel;Claudia Bredel;Dejan Juric;Griffith R. Harsh

  • Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

    Bert L. Lum;Sonia Kaubisch;Anne M. Yahanda;Kent M. Adler

  • Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

    Peter L. Greenberg;Sandra J. Lee;Ranjana Advani;Martin S. Tallman

  • NFKBIA Deletion in Glioblastomas

    Markus Bredel;Denise M. Scholtens;Ajay K. Yadav;Angel A. Alvarez

  • Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.

    Harker Wg;Sikic Bi

  • Modulation of multidrug resistance: at the threshold.

    B I Sikic

  • Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

    A M Yahanda;K M Alder;G A Fisher;N A Brophy

  • Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion

    John J. Gullo;John J. Gullo;Charles L. Litterst;Patrick J. Maguire;Patrick J. Maguire;Branimir I. Sikic;Branimir I. Sikic

  • Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro.

    S Weber;J E Zuckerman;D G Bostwick;K G Bensch

  • Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance

    Kevin G. Chen;Branimir I. Sikic

  • High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

    Markus Bredel;Claudia Bredel;Claudia Bredel;Dejan Juric;Griffith R. Harsh

  • Integrated genomic analyses of ovarian carcinoma

    D. Bell;A. Berchuck;M. Birrer;J. Chien

Frequent Co-Authors

Heather A. Wakelee
Heather A. Wakelee Stanford University
Ranjana H. Advani
Ranjana H. Advani Stanford University
Hannes Vogel
Hannes Vogel Stanford University
Robert Tibshirani
Robert Tibshirani Stanford University
Nelson J. Chao
Nelson J. Chao Duke University
Howard J. Weinstein
Howard J. Weinstein Harvard University
Susana C. Raimondi
Susana C. Raimondi St. Jude Children's Research Hospital
Tibor Keler
Tibor Keler Bristol-Myers Squibb (United States)
Irving L. Weissman
Irving L. Weissman Stanford University
Amita Patnaik
Amita Patnaik University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring health careers beyond medical school can open a wide range of opportunities in the healthcare sector. For those passionate about patient care but seeking an alternative pathway, becoming a registered nurse is a popular choice. There are nursing school that doesn't require teas or HESI exams, making entry into the field more accessible.

If you are interested in leadership or administrative roles in healthcare, pursuing an accelerated healthcare administration degree can fast-track your career, allowing you to manage hospitals, clinics, or health organizations.

RNs looking to advance their education and clinical expertise can consider dedicated rn to np bridge programs to transition into nurse practitioner roles. These programs are designed for working professionals and streamline the journey from ADN to MSN.

Lastly, nutrition is a fast-growing area in healthcare. Accredited nutrition degrees online let students learn about dietetics, health promotion, and wellness—skills that are in high demand in hospitals, public health, and private practice.

Best Scientists Citing Branimir I. Sikic

Trending Scientists

Recently Published Articles